Rize Oncology Inc.
CNSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -21.29% | -8.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.20% | 51.33% | |||
| Operating Income | 9.20% | -51.33% | |||
| Income Before Tax | 7.71% | -50.94% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 7.71% | -50.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.71% | -50.94% | |||
| EBIT | 9.20% | -51.33% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 7.55% | -47.22% | |||
| Normalized Basic EPS | 6.06% | -43.48% | |||
| EPS Diluted | 7.55% | -47.22% | |||
| Normalized Diluted EPS | 6.06% | -43.48% | |||
| Average Basic Shares Outstanding | 0.00% | 3.86% | |||
| Average Diluted Shares Outstanding | 0.00% | 3.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||